Valuation : GlaxoSmithKline Pakistan Limited

Market Cap 104B 374M 323M 304M 277M 520M 35.5B 523M 3.59B 1.4B 18.06B 1.4B 1.37B 59.88B P/E 2026 *
10x
P/E 2027 * 8.31x
Enterprise Value 104B 374M 323M 304M 277M 520M 35.5B 523M 3.59B 1.4B 18.06B 1.4B 1.37B 59.88B EV / Sales 2026 *
1.51x
EV / Sales 2027 * 1.39x
Free-Float
16.89%
Yield 2026 *
5.43%
Yield 2027 * 6.27%
08-29 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
08-25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-25 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026 CI
08-03 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
08-03 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
06-01 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
04-27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-09 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
04-07 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
1 day-0.86%
1 week-3.14%
Current month-0.86%
1 month-3.93%
3 months-4.10%
6 months-10.88%
Current year-14.80%
1 week 331.1
Extreme 331.1
345.5
1 month 331.1
Extreme 331.1
356
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 69.06
Extreme 69.06
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.86%-3.14%-18.56%+374.40% 381M
+1.49%-0.28%+61.33%+112.49% 1,034B
+1.48%+2.91%+56.04%+72.92% 654B
-0.18%-0.87%+22.98%+78.38% 459B
+0.94%-4.51%+34.24%+36.50% 343B
-0.34%+3.27%+29.78%+47.52% 307B
+0.59%-1.06%+1.68%+13.23% 251B
+0.25%+0.13%+53.67%+73.58% 237B
+2.26%-0.84%-15.64%-53.86% 202B
+0.23%+1.91%+33.91%+100.80% 186B
Average +0.59%-2.91%+25.94%+85.60% 367.2B
Weighted average by Cap. +0.88%-3.31%+40.23%+69.67%

Financials

2026 *2027 *
Net sales 68.81B 248M 214M 201M 183M 345M 23.55B 347M 2.38B 927M 11.98B 932M 912M 39.73B 74.58B 269M 232M 218M 199M 374M 25.53B 376M 2.58B 1B 12.98B 1.01B 988M 43.05B
Net income 10.49B 37.83M 32.63M 30.7M 27.97M 52.59M 3.59B 52.87M 363M 141M 1.83B 142M 139M 6.06B 12.42B 44.79M 38.64M 36.35M 33.11M 62.27M 4.25B 62.6M 430M 167M 2.16B 168M 165M 7.17B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
01/09/26 PKR 332.08 -0.86% 646,217
31/08/26 PKR 334.97 -1.12% 344,884
28/08/26 PKR 338.78 -1.35% 240,952
27/08/26 PKR 343.41 +0.17% 322,065
25/08/26 PKR 342.84 +0.54% 596,822
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
332.08PKR
Average target price
510.00PKR
Spread / Average Target
+53.58%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock